Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.
“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.
Personalized immunotherapy is a fast-growing field of research in the fight against cancer.
The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.
Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.
“The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon said.
The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.
When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.
“This suggests the immune system ‘remembered’ the cancer cells for long-term immunity,” said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.
“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon said.
The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.
“It’s a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy,” said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.
The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.
Receive an email update when we add a new PERSONALIZED IMMUNOTHERAPY article.
The Latest on: Personalized immunotherapy
via Google News
The Latest on: Personalized immunotherapy
- Innovative immunotherapy improving quality of life for Lantzville teen with canceron November 29, 2019 at 11:02 pm
Michelle had been enrolled in BC Cancer’s Personalized Onco-Genomics (POG) Program, funded by generous donors. Experts had sequenced the entire DNA of her tumour and discovered it might respond to ...
- Engineering dendritic cell vaccines to improve cancer immunotherapyon November 27, 2019 at 2:23 am
However, DC vaccines have yet to be fully realized as an immunotherapy. Although genetically engineered cell therapies have ... leveraging the flexibility of cDC1s toward a truly personalized ...
- Artificial Intelligence Predicts Lung Cancer Immunotherapy Successon November 26, 2019 at 9:52 am
“Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive—about $200,000 per patient, per year,” said Anant Madabhushi, director of the Center for ...
- AI predicts response of lung cancer patients to immunotherapyon November 25, 2019 at 9:05 pm
While immunotherapy is a rapidly growing and promising field in cancer research ... director of Case Western Reserve University’s Center for Computational Imaging and Personalized Diagnostics.
- EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastomaon November 25, 2019 at 4:06 pm
RRx-001 is a next generation small molecule immunotherapy being developed by EpicentRx ... The company is also advancing multiple programs through its smart virus platform, including personalized ...
- AI Can Determine if Immunotherapy is Working for Patientson November 25, 2019 at 10:21 am
At about $200,000 per patient per year, combined with the small success rate sample size, immunotherapy can not be considered a large-scale cancer cure/treatment—yet. Researchers at the Center for ...
- AI to determine if immunotherapy is working in lung canceron November 23, 2019 at 7:27 pm
New York, Nov 23 : Scientists who have pioneered the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit ...
- AI Helps Determine If Immunotherapy Works in Lung Canceron November 23, 2019 at 11:19 am
‘Currently, only about 20 per cent of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy ... whose Center for Computational Imaging and ...
- Using artificial intelligence to determine whether immunotherapy is workingon November 23, 2019 at 5:59 am
whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing ...
via Bing News